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Abstract
The kynurenine pathway (KP) is a key regulator of many important physiological processes and 
plays a harmful role in cancer, many neurological conditions, and chronic viral infections. In HIV 
infection, KP activity is consistently associated with reduced CD4 T cell counts, and elevated 
levels of T cell activation and viral load (VL); it also independently predicts mortality and 
morbidity from non-AIDS events. Kynurenine 3-monooxygenase (KMO) is a therapeutically 
important target in the KP. Using the non-human primate model of simian immunodeficiency virus 
(SIV) infection in rhesus macaques, we investigated whether KMO inhibition could slow the 
course of disease progression. We utilized a KMO inhibitor (KMOi), CHDI-340246, to perturb the 
KP during early acute infection and followed the animals for one year to assess clinical outcomes 
and immune phenotype and function during pre-cART acute infection and cART-treated chronic 
infection. Inhibition of KMO in acute SIV infection disrupted the KP and prevented SIV-induced 
increases in downstream metabolites, improving clinical outcome as measured by both increased 
CD4+ T cell counts and body weight. KMO inhibition increased naïve T cell frequency and 
lowered PD-1 expression in naïve and memory T cell subsets. Importantly, early PD-1 expression 
during acute SIV infection predicted clinical outcomes of body weight and CD4+ T cell counts. 
Our data indicate that KMO inhibition in early acute SIV infection provides clinical benefit, and 
suggest a rationale for testing KMO inhibition as adjunctive treatment in SIV/HIV infection to 
slow progression of disease and improve immune reconstitution.
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Introduction
Progressive HIV disease is marked by systemic inflammation and immune dysregulation, 
most notably CD4+ T cell depletion (1–4). The persistence of immune activation, even in 
long-term cART-treated individuals, is associated with increased risk of AIDS and non-
AIDS morbidities, including cardiovascular disease, cancers, and modulated neurocognition 
(5, 6). Several factors have been identified as associated with immune dysfunction and 
disease progression; for example, KP metabolites and the increased expression of inhibitory 
molecules like PD-1 (7–11).
The KP is the principal pathway by which tryptophan (TRP) is metabolized, and is a key 
regulator of many important physiological processes such as energy production, protein 
synthesis, immune response, and excitatory neurotransmission (12–15). The rate-limiting 
step of the KP is the conversion of TRP to kynurenine (KYN) by IDO, which is inducible by 
inflammatory stimuli. KYN is usually hydroxylated to 3-hydroxy kynurenine (3HK) by 
kynurenine 3-monooxygenase (KMO) and then further converted to 3-hydroxy anthranilic 
acid (3HAA). 3HAA is rapidly converted to quinolinic acid (QA), and proceeds with 
conversion to NAD+, a preferred end product of the KP (13).
Many studies have shed light on the role of the KP, suggesting that it plays a harmful role in 
cancer, many neurological conditions, and chronic viral infections such as HIV (10, 16). 
Monocyte-derived dendritic cells (DCs )expressing IDO promote regulatory T cell (Treg) 
expansion (17). KP metabolites can also act as aryl hydrocarbon receptor (AhR) ligands, 
which allow the generation of Treg cells (18). In addition, several KP metabolites inhibit T 
cell proliferation directly, further contributing to a hyperinflammatory state (19), while QA 
damages brain tissue leading to dementia (20). We and others have shown that IDO and 
KMO activity leads to loss of Th17 cells, which play an important role in maintaining the 
gut mucosal epithelial barrier (9, 10, 21–23). This reduction in Th17 cells was found to be 
mediated by 3HAA, a downstream metabolite of KYN and KMO activity (10), and can 
result in microbial translocation and systemic inflammation (24).
In HIV infection, IDO activity, is consistently linked to reduced CD4 T cell counts, and 
elevated levels of T cell activation and VL (11, 25). In addition, the KYN/TRP ratio 
independently predicts mortality and morbidity from non-AIDS events (5, 6, 25, 26). The 
KP has also been implicated in the pathogenesis of HIV associated neurocognitive disorder 
(HAND); for example, neurotoxic QA is elevated in the cerebrospinal fluid of patients with 
AIDS dementia (20, 27).
KMO is a therapeutically important target in the KP (28–31), where it converts KYN to 
3HK. Inhibition of this enzyme shifts the flux in the pathway towards the formation of 
neuroprotectant kynurenic acid (KYNA), and away from the ROS-generating and toxic 
metabolites, 3HK and QA (29). Notably, KMO expression is higher in pro-inflammatory 
than in anti-inflammatory macrophages (32), and increases in inflammatory conditions or 
after immune stimulation (33).
Based on the extensive research indicating that the KP is detrimental in HIV infection, we 
investigated whether KMO inhibition could impact the course of HIV disease progression 
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utilizing a well-established model of SIV infection in rhesus macaques. We utilized a KMOi, 
CHDI-340246, to perturb the KP during the first 4 weeks of infection (a period during acute 
infection when KP activity is a key discriminator between pathogenic and non-pathogenic 
SIV infection (9)) and followed the animals for one year to assess clinical and 
immunological outcomes during pre-cART acute infection and cART-treated chronic 
infection. Our data indicate that such KMO inhibition provides clinical benefit in SIV 
infection, and suggest a rationale for testing KMO inhibition as adjunctive treatment in 
SIV/HIV infection.
Materials and Methods
Study design
16 male rhesus macaques of 4–5 years of age were intravenously challenged with 
SIVmac251 after testing negative for SRV, STLV, hepatitis B, and helminthic infections. The 
viral stock was previously characterized and obtained from Nancy Miller (NIH). 8 animals 
received KMOi CHDI-340246 (10 mg/kg) daily via oral gavage, and the other 8 control 
animals received vehicle only for 4 weeks, commencing the day prior to SIV infection. 
Peripheral blood was sampled to evaluate the pharmacokinetics and pharmacodynamics 
(PK/PD) of CHDI-340246, VL, CD4+ T cell counts, immune phenotype and function, and 
microbial translocation. Rectal pinch biopsies (RB) and peripheral lymph node (LN) 
biopsies were taken to understand the impact of KMO inhibition on tissue immune 
phenotype and function. The study design and schedule is shown in Fig 1.
After the 4 week treatment period with CHDI-340246, animals were followed for an 
additional 50 weeks post infection (p.i.). At 14 weeks p.i., animals commenced a cART 
treatment regimen of once daily subcutaneous injections of tenofovir (TFV, Gilead), 20 
mg/kg, emtricitabine (FTC, Gilead), 40 mg/kg, and dolutegravir (DTG, ViiV), 2.5 mg/kg 
until study completion at 54 weeks p.i. All protocols were approved before implementation 
by the Institutional Animal Care and Use Committee at Bioqual, Inc. Health, food intake, 
and body weights were recorded regularly according to established protocols.
Phenotypic analysis of lymphocyte populations
Thawed PBMCs were surface stained with Aqua amine reactive viability dye (Invitrogen) 
and mAbs to CD45 (clone D058–1283, BD Biosciences), CD3 (clone SP34–2, BD 
Biosciences), CD4 (clone L200, BD Biosciences), CD8 (clone 3B5, Invitrogen), CD95 
(clone DX2, BioLegend), CD28 (clone CD28.2, Beckman), CD127 (clone hIL-7R-M21, BD 
Biosciences), PD-1 (clone EH12.2H7, BioLegend), and HLA-DR (clone L243, BD 
Biosciences) for 20 min at room temperature, fixed, and then permeabilized with FoxP3 Fix/
Perm Buffers (eBioscience) per the manufacturer’s instructions. Permeabilized cells were 
then stained intracellularly for Ki67 (clone B56, BD Biosciences) and FoxP3 (clone 
PCH101, eBioscience) for 30 min at 4°C, washed in FoxP3 Perm/Wash buffer, fixed in 0.5% 
paraformaldehyde and analyzed by flow cytometry on a BD LSRII flow cytometer (BD 
Biosciences) and analyzed using Flowjo Software (Tree Star Inc).
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Cytokine Flow Cytometry (CFC)
Analysis of IL-2, IL-17, IL-4, IFNα, and TNFα production in PMA/ionomycin or p27 (Gag) 
peptide stimulated CD4+ or CD8+ T cells was carried out by cytokine flow cytometry, as 
previously described (34). Fixed and permeabilized cells were analyzed by flow cytometry 
on a BD LSRII flow cytometer (BD Biosciences) and analyzed using Flowjo Software (Tree 
Star Inc).
ELISAs
Plasma was stored at −80°C prior to analysis. Cytokines were measured using ELISA kits 
for sCD14 (R&D Systems), IP-10 (R&D Systems), sTNFRα1 (R&D Systems), and IL-7 
(R&D Systems), according to the manufacturers’ instructions.μ
Quantification of KMOi CHDI-340246 in plasma
Determination of CHDI-340246 in monkey plasma was performed using a liquid 
chomatography-tandem mass spectrometry (LC/MS/MS) method. A 25 μL aliquot of plasma 
was mixed with 200 μL of methanol:acetonitrile (50:50; v:v) containing CHDI-340246-d3 
(100 ng/mL) as internal standard followed by centrifugation for 5 min at 3000 rcf. A 50 μL 
aliquot of supernatant was removed and mixed with 300 μL of 0.1% ammonium hydroxide 
in water at 1000 rcf for 1 min and then held at 4°C until analyzed by HPLC/MS. The 
supernatant was analyzed by injecting 10 μL onto an Agilent Pursuit XRs C18 (2.0 × 50 
mm, 3 μm) column maintained at 40°C. The mobile phase flow rate was 0.7 mL/min and 
initial conditions comprised of 50% 10 mM ammonium bicarbonate and 0.4% ammonium 
hydroxide in water (mobile phase A) and 50% 10 mM ammonium bicarbonate and 0.4% 
hydroxide in methanol:water (90:10; v/v)(mobile phase B). The separation of CHDI-340246 
was achieved using a gradient that increased from 50% mobile phase B at time 0 to 80% 
mobile phase B at 1.7 min with initial conditions returning at 2 min. The mass spectrometer 
used was API 4000 with TurboSpray in positive ionization mode. The transition ions (m/z) 
monitored were 291.1 → 218.0 for CHDI-340246 and 296.1 → 223.0 for CHDI-340246-d3 
(the 37Cl isotope of the internal standard was monitored to avoid contribution from the 
analyte). The calibration standard range was 10 ng/mL to 10,000 ng/mL and the lower limit 
of quantitation (LLOQ) was 10 ng/mL. CHDI-340246 was found to be stable in plasma 
following storage at −20°C up to 3 months and following freeze/thaw cycle.
Quantification of KP metabolites in plasma
Determination of KP metabolites in plasma were determined using 3 separate LC/MS/MS 
methods. A 5-analyte method was used for simultaneous analysis of KYN, KYNA, 3HK, 
AA and 3HAA. A second method was used for analysis of QA and a third method was 
employed to quantitate TRP in plasma. The stability of KP metabolites in plasma following 
storage at −20°C up to 3 months and following freeze-thaw cycle was established prior to 
analysis of the samples. For the 5-analyte method, a 200 μL aliquot of plasma was first 
mixed with 25 μL of 10% ascorbic acid followed by addition of 50 μL of internal standard 
solution (acetonitrile:water; 50:50) containing KYN-D6 (100 ng/mL), KYNA-D5 (50 ng/
mL), 15N13C2 3HK (100 ng/mL), and 13C6 AA (50 ng/mL). To this mixture, 800 μL of 
acetonitrile/methanol (90:10; v:v) was added to precipitate the proteins. After mixing and 
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centrifugation, a 700 μL aliquot of supernatant was transferred to a clean tube and 
evaporated at 40°C for up to 2 h using TurboVap. The dried extract was then reconstituted 
with 100 μL of 0.1% formic acid in water. The separation of analytes was achieved by 
injecting 25 μL of reconstituted extract on a Waters XSelect HSS T3 (2.1 × 50 mm, 2.5 μm) 
column maintained at ambient temperature. The mobile phase (flow rate - 0.4 mL/min) was 
comprised of 0.1% formic acid in HPLC grade water (mobile phase A) and 100% 
acetonitrile (mobile phase B) with 0% B at initial conditions (time 0) and gradient starting at 
0.1 min and reaching up to 95% B at 3.8 min, which was then maintained up to 4.3 min. 
Using API 5000 mass spectrometer with MRM scan mode and Turbospray ionization in 
positive mode, the transition ions monitored were as follows: KYN, 290.2 → 94.0; KYNA, 
190.0 → 162.0; 3-HK, 225.1 → 162.1; AA, 138.0 → 92.0; 3-HAA, 154.0 → 108.0; 
KYN-D6, 215.2 → 98.0; KYNA-D5, 195.0 → 167.0; 15N13C2 3-HK, 228.1 → 163.1, and 
13C6 AA, 144.1 → 98.0. The calibration ranges were 200 ng/mL to 160,000 ng/mL for 
KYN, 2.0 to 1600 ng/mL for KYNA and 3-HK, 5.0 to 4000 ng/mL for AA, and 20.0 to 
16000 ng/mL for 3-HAA. The LLOQ was 200, 2.0, 2.0, 5.0, and 20.0 ng/mL for KYN, 
KYNA, 3-HK, AA, and 3-HAA, respectively.
For analysis of QA in plasma, a 30 μL aliquot was mixed with 30 μL of internal standard 
solution containing QA-D3 (250 ng/mL) followed by addition of 120 μL of 
methanol:pyridine (80:20; v:v). The mixture was centrifuged at 3000 rcf at 4°C for 10 min 
and a 100 μL of supernatant was transferred to a clean tube and mixed with 45 μL of 0.5M 
NaOH and then centrifuged. QA and internal standard were derivatized by adding 20 μL of 
methyl chloroformate and then mixing for 10 min at 500 rpm. Following mixing, 600 μL of 
2% formic acid was added and the sample was centrifuged at ~3000 rcf for 5 min. The 
supernatant was injected on an Ascentis Express Phenyl-Hexyl (3 × 75 mm, 2.7 μm) column 
maintained at 40°C. The mobile phase flow rate was 0.45 mL/min and comprised of 5 mM 
ammonium formate /acetonitrile (85:15)(mobile phase A) and acetonitrile (mobile phase B) 
with initial conditions set at 4% mobile phase B and maintained up to 3.0 min, changing to 
100% at 3.10 min and then reversing back to 4% B at 3.7 min. The mass spectrometer used 
was API 5000 with TurboSpray and in positive ionization mode. The transition ions 
monitored were 194.4 → 164.2 for QA and 199.4 → 167.2 for QA-D3. The calibration 
standard range was 20 ng/mL to 20,000 ng/mL and the LLOQ was 20 ng/mL.
For analysis of TRP in plasma, a 25 μL aliquot was mixed with 400 μL of internal standard 
solution (acetonitrile/methanol; 90:10) containing TRP-D5 (5000 ng/mL). Following mixing 
for 1 min at 1000 rpm, the samples were centrifuged at 3000 rcf for 5 min. A 50 μL of 
supernatant was transferred to a clean tube containing 800 μL of 0.1% formic acid. The 
supernatant was analyzed by injection on a Waters Xbridge C18 (2.1 × 50 mm, 2.5 μm) 
column maintained at 40°C. The mobile phase flow rate was 0.4 mL/min and comprised of 
0.1% formic acid in water (mobile phase A) and 0.1% in acetonitrile (mobile phase B). The 
initial conditions were 5%B which increased to 30%B from 0.3 min to 1.2 min and then to 
98% at 1.3 min which were maintained up to 1.8 min and then returning to initial conditions 
at 1.9 min. Using an API 4000 mass spectrometer, with TurboSpray in positive ionization 
mode, the transition ions monitored were 205.1 → 146.1 for TRP and 210.1 → 150.0 for 
TRP-D5. The calibration standards range was 500 ng/mL to 500,000 ng/mL and the lower 
limit of quantitation (LLOQ) was 500 ng/mL.
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For all methods described above, each run was monitored by including quality controls 
(QCs) at 4 levels (low, low-mid, mid, and high) and acceptability of the concentration data 
for each analyte was based on ±15% CV for all QCs, except for low QC where acceptability 
was based on ±20% CV.
Immunohistochemistry (IHC) and in situ hybridization (ISH)
IHC, ISH and quantitative image analysis was performed for collagen, MPO, TGFβ and 
IL-17 on RB and inguinal LN samples, as previously described (35–39). IL-17 (A83173, 
Sigma), MPO (A0398, DAKO), and TGFβ (sc-146-G, Santa Cruz) IHC staining were 
performed on formalin-fixed, paraffin-embedded LN and/or RB tissue of 5 μm sections; 
collagen deposition was evaluated using Picro Sirius Red and light green staining. Entire 
tissue sections were scanned at high magnification (×200) using the ScanScope AT2 System 
(Aperio Technologies), then representative regions of interest (500 × 500 μm) were 
identified and high-resolution images extracted. The % area of each positive staining was 
quantified using Cell Profiler.
Statistical analysis
Differences between treatment groups in the change from baseline were assessed with linear 
mixed models (STATA 14.2), transforming outcome variables as appropriate to satisfy model 
assumptions. Timepoint by treatment group interaction terms were used to assess whether 
the change from baseline at each timepoint differed by treatment group. When more than 
one pre-SIV infection timepoint was available for a given analyte, all values contributed to 
each animal’s baseline estimate to improve precision. When consistent trends were evident 
across multiple timepoints, post-hoc analyses were conducted to assess the significance of 
those trends across all timepoints. Significance was defined as P < 0.05. For the PK/PD data, 
differences between treatment groups at indicated timepoints was assessed using Wilcoxon 
rank sum analysis.
Results
Study Design
To determine whether inhibition of KMO might have an impact on acute SIV infection, 16 
rhesus macaques were infected i.v. with SIVmac251. 8 animals were treated for 4 weeks 
with 10 mg/kg/day of the KMOi, CHDI-340246, and 8 animals served as vehicle only 
controls, starting the day prior to infection. Between 12 and 14 weeks p.i., 3 animals (2 
controls and 1 KMOi-treated animal) were euthanized due to AIDS-related symptoms. At 14 
weeks p.i., all remaining animals were placed on cART until study completion at 54 weeks 
p.i. In addition to PK/PD evaluation and monitoring of VL and CD4+ T cell counts, 
measures of immune phenotype and function were collected from peripheral blood, inguinal 
LN, and RB at the timepoints indicated in Fig. 1.
KMO inhibition increases CD4+ T cell counts and body weight in SIV-infected animals
To establish whether KMO inhibition has an impact on clinical outcomes in SIV infection, 
peripheral blood CD4+ T cell counts, body weight, and plasma RNA VL were measured 
(Figs. 2A, B, and C). After cART initiation, CD4+ T cell counts between the groups 
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diverged and KMOi-treated animals demonstrated significantly higher CD4+ T cell counts at 
32 and 52 weeks p.i (Fig. 2A). A consistent increase in CD4+ T cell counts across all 
timepoints was apparent during cART in the KMOi-treated group. This trend was formally 
tested using linear mixed models, with KMOi-treated animals experiencing a mean 29 
cell/mm3 greater CD4+ T cell count increase than placebo-treated animals across all 
timepoints after cART initiation (P=0.033).
The juvenile macaques used in this study exhibited continued growth despite SIV infection, 
as expected. Body weight increased equivalently in both treatment groups until 7 weeks after 
cART initiation, when growth trends diverged (Fig. 2B.). These trends became more 
pronounced over time, with KMOi-treated animals exhibiting significantly greater weight 
gain than the vehicle-treated controls at almost all timepoints after 28 weeks p.i. By the end 
of the study, KMOi-treated animals had gained double the weight of the controls (+45% of 
baseline weight vs. +22% of baseline weight, respectively).
No significant differences were observed in plasma RNA VL between treatment groups at 
any timepoint (P > 0.05) (Fig. 2C). The time to achieve undetectable virus (< 50 copies/ml) 
was highly variable and dependent on set point VL rather than treatment status. At 36 weeks 
p.i. (22 weeks after cART initiation), undetectable VL was achieved in 10/13 animals, with 
occasional ‘blipping’ occurring in some animals. Two animals retained VL of 104 - 105 
copies/ml until 44 weeks p.i. when darunavir (800 mg/day) was supplemented to their cART 
regimen. Notably, these animals had the highest VL pre-cART (7×108 and 3×109 copies/ml), 
despite higher than average CD4+ T cell counts.
KMOi CHDI-340246 disrupts the KP and prevents SIV-induced increases in downstream 
metabolites
To determine the PK of CHDI-340246, drug levels were measured in plasma by LC/MS/MS. 
Cmax reached 96 μM after first dose, with Tmax of 2.5 h, and a drug half-life of 6.3 h (Fig. 
3B). Of note, there were no significant differences in PK parameters between the first and 
the last dose, indicating that drug clearance mechanisms were not affected by the treatment 
itself (Fig. 3B).
To understand the impact of KMOi administration on KMO activity, plasma concentrations 
of TRP, KYN, its KMO-catalyzed metabolite 3HK, KYN-level alternative branch 
metabolites anthanilic acid (AA) and kynurenic acid (KYNA), and the 3HK downstream 
metabolite QA were measured by LC/MS/MS (Fig. 3C). CHDI-340246 is highly selective 
for KMO vs other enzymes in the kynurenine pathway (40). Effective inhibition of KMO 
activity should increase the concentration of KYN, AA and KYNA, and decrease the 
concentration of 3HK and QA, leaving TRP levels unchanged. (Fig. 3A). These patterns 
were indeed observed, with CHDI-340246-treated animals reaching KYN, KYNA, and AA 
Cmax of 1–2 orders of magnitude higher than the control animals, and 3HK and QA 
concentrations in treated animals dropping to approximately one third the levels present in 
control animals (Fig. 3C).
Fig. 3D shows trough plasma concentrations of KYN and QA thoughout the first 56 days, 
during which animals were dosed daily with either KMOi CHDI-340246 or vehicle for the 
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first 28 days. As expected, SIV infection in the control group induced increased 
concentrations of both KYN and QA, peaking at 11 days p.i. The disruptive effect of KMO 
inhibition on the KYN pathway was to increase the KYN levels above that in the control 
group after infection and to completely inhibit any increase in QA levels above baseline 
levels thoughout the dosing period (Fig. 3D). At 42 days p.i., metabolite levels in both 
groups were equivalent, indicating complete drug wash out by 2 weeks after the end of 
dosing.
The KMOi CHDI-340246 was safe at the treatment dose used in this study. Complete blood 
count and extensive chemistry tests were performed to evaluate, e.g., RBC, WBC, 
hemoglobin, platelets, liver and kidney function, electrolytes and minerals (data not shown). 
In addition, animals were monitored closely for any abnormal clinical signs or behavior. No 
toxicities or safety concerns arose in the KMOi-treated animals.
KMO inhibition lowers PD-1 expression in CD4+ and CD8+ T cells of SIV-infected animals
The KP pathway has been implicated in altering immune activation and clinical outcomes in 
HIV/SIV infection (9, 10, 21, 22). To determine whether KMOi treatment inhibited T cell 
activation, expression levels of PD-1, HLA-DR, and cell cycle marker Ki67 were studied by 
flow cytometry in inguinal LN biopsies. Control and KMOi-treated animals showed 
different patterns of T cell activation. PD-1 expression in CD4+ T cells (Fig. 4A) rose during 
acute SIV infection to peak at 12 weeks p.i. before gradually diminishing, but this increase 
in PD-1 expression was blunted in the KMOi-treated animals, with significantly less 
expression at 12 weeks p.i. (P < 0.05). A trend towards lower PD-1 in the treated group was 
apparent up to 40 weeks p.i., even though dosing of KMOi ceased at 4 weeks p.i. Lower 
Ki67 expression in the treated group was also evident at 8 weeks p.i. (Fig. 4A), with a 
similar pattern observed for CD8+ T cells (Fig. 4B).
In PBMCs, significantly lower levels of PD-1 expression were also evident, in addition to 
lower expression of HLA-DR and Ki67 in both CD4+ and CD8+ T cells (Supplemental Fig. 
1). Analysis of other parameters of immune phenotype and function showed no difference 
between the KMOi-treated and control groups. No differences between groups were noted in 
levels of IP-10, TNFRα1, and sCD14 soluble markers of immune activation from plasma 
(data not shown). Since the checkpoint inhibitor PD-1 is upregulated on exhausted T cells 
(8, 41), and blockade of this molecule can increase T cell functionality (41–44), bulk CD4+ 
and CD8+ T cells were assessed by CFC to determine whether KMO inhibition increased 
polyfunctional or SIV-specific IFNα, TNFα, IL-2 or IL-17 production above that in control 
animals, however, this was not observed (Supplemental Fig. 4 and data not shown).
KMO inhibition increases naïve T cell frequency in SIV-infected animals
To evaluate whether KMO inhibition modified the proportions of naïve and memory cells, T 
cell expression of CD95 and CD28 was determined by flow cytometry from cells isolated 
from inguinal LN. Naïve T cells were defined as CD95-CD28+, central memory (CM) T 
cells as CD95+CD28+, and effector memory (EM) T cells as CD95+CD28-. Higher 
frequencies of naïve cells were present in both CD4+ (Fig. 5A) and CD8+ T cells (Fig. 5B) 
in KMOi-treated animals, manifesting at 8 weeks p.i. when these differences were 
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statistically significant (P < 0.05), and sustained at higher levels than those seen in controls 
until 40 weeks p.i. These higher proportions of naïve T cells were counterbalanced by lower 
frequencies of CM cells, while proportions of EM were similar between groups in both 
CD4+ and CD8+ T cells. While the difference between treatment groups was not as striking 
as that seen in LN, higher proportions of naïve and lower proportions of CM T cells was also 
evident in both CD4+ and CD8+ PBMC T cells (Supplemental Fig. 2).
We hypothesized that the increased proportions of naïve T cells may be due to greater 
thymic function or thymocyte survival in the presence of KMOi, as downstream KP 
metabolites can induce thymocyte apoptosis (45). Since cryopreserved cells were not 
available to measure thymic output by T cell receptor excision circles (46), we instead 
evaluated the activity of KMOi CHDI-340246 in SCID-hu Thy/Liv mice inoculated with 
HIV-1 NL4–3. No significant differences were observed in thymic cellularity, CD4/CD8 
frequencies, or VL (data not shown), suggesting either that mechanisms unrelated to thymic 
function or thymocyte survival may have resulted in the observed modified proportions of 
naïve/memory cells in the KMOi-treated rhesus macaques, or that such mechanisms were 
not revealed in the SCID-hu experiments that we performed.
KMO inhibition lowers PD-1 expression within naïve and memory T cell subsets of SIV-
infected animals
PD-1 is expressed on a greater frequency of memory cells than naïve cells (47, 48). To 
determine whether the higher proportion of naive cells in the KMOi-treated animals (Fig. 5) 
explained the lower frequency of PD-1 expression (Fig. 4), PD-1 expression was analyzed 
within the naïve, CM, and EM CD4+ and CD8+ T cell subsets of LN (Fig. 6). Although in 
the absence of HIV/SIV infection, naïve T cells express negligible PD-1, HIV/SIV infection 
induces PD-1 expression on a fraction of naïve T cells (48). This was also observed in our 
study, with >10% of CD4+ naïve T cells and >20% of CD8+ naïve T cells in the control 
group expressing PD-1 at 8 weeks p.i. Significantly fewer naïve and CM CD4+ T cells from 
KMOi-treated animals expressed PD-1 at 12 weeks p.i., and there was a trend for lower 
frequencies of PD-1 expression within all CD8+ T cell subsets. These data indicate that 
lower proportions of PD-1-expressing cells on bulk T cells were not merely the result of the 
KMOi modifying proportions of naïve and memory T cells; indeed, PD-1 expression was 
intrinsically lower within both naïve and memory populations. In addition, the PD-1 MFI 
was lower in the KMOi treated animals in total, naïve, central memory, and effector memory 
gated PD-1+ populations (Supplemental Fig. 3).
Early PD-1 expression during acute SIV infection predicts clinical outcomes of body 
weight and CD4+ T cell counts
A striking feature of the clinical outcomes of KMO inhibition shown in Figs. 2A and 2B is 
that the differences between treatment groups only became apparent after cART initiation, 
and reached statistical significance 6 months p.i., even though KMOi was only administered 
for the first 4 weeks of the study. By contrast, immunological outcomes (reduced PD-1 
expression and increased naïve T cell frequencies), (Figs. 4–6), were evident either at the 
end of the dosing phase or shortly thereafter. To determine whether early PD-1 expression in 
acute infection predicted clinical outcomes of body weight and CD4+ T cell counts later in 
Swainson et al. Page 9
J Immunol. Author manuscript; available in PMC 2020 August 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
the study, we performed linear regressions between the frequency of PD-1+ T cells at −2, 4, 
and 8 weeks p.i. and the outcome variables of body weight (Fig. 7A) and CD4+ T cell 
counts (Fig. 7B) at 48 weeks p.i.
For body weight at 48 weeks p.i., significant (P < 0.05) negative relationships were found 
for PD-1 expression at week 8 in CD4+ T cells and at week 4 in CD8+ T cells (Fig. 7B). 
Similar data were observed when expression of PD-1 was assessed as a predictor of outcome 
CD4+ T cell counts (Fig. 7B). However, no correlation was observed between PD-1 
expression at pre-infection baseline and either clinical outcome at 48 weeks p.i., suggesting 
that modulation of PD-1 by KMOi may be predictive of slower disease progression.
To determine if retention of Th17 cells may be a potential mechanism for the beneficial 
actions of KMOi in this study, IL-17+ CD4+ T cells were measured by CFC. The frequency 
of IL-17+ CD4+ T cells dropped during acute infection in both groups, and then gradually 
recovered after 6 weeks p.i, as expected. As the frequency increased, however, the % of 
CD4+ cells expressing IL-17 in KMOi-treated animals never reached the IL-17 frequencies 
detected in control animals (Supplemental Fig. 4A). IHC staining of IL-17 was performed in 
inguinal LN and RB gut samples to determine whether Th17 levels in tissues may have been 
modulated by KMOi. No significant differences were observed between treatment groups 
(Supplemental Fig. 4B and 4C). To evaluate whether microbial translocation may have 
played a role in the effects of KMO inhibition independent of IL-17, we measured proxies 
for microbial translocation: sCD14 in plasma by ELISA and neutrophil infiltration in RB by 
myeloperoxidase (MPO) IHC staining. Both analytes initially increased during acute SIV 
infection, but measurements out to 12 weeks p.i. indicated no differences between treatment 
groups (data not shown).
During HIV/SIV infection, Treg recruited into lymphoid tissues produce TGFβ (49), 
inducing fibroblasts to produce collagen that eventually replaces the fibroblastic reticular 
cell network (FRCn); this results in the loss of the important T cell survival cytokine IL-7 
(49–51) and leads to naïve T cell depletion (52). To investigate whether KMOi inhibited 
these processes, collagen deposition and TGFβ expression were analyzed in LN by IHC 
staining, Treg frequencies were monitored by flow cytometry, and IL-7 levels were 
measured in plasma by ELISA. No significant differences in any of these parameters were 
observed between treatment groups (data not shown).
Discussion
These data demonstrate that inhibition of KMO in acute SIV infection disrupts the KP and 
prevents SIV-induced increases in downstream metabolites, with the resultant effect of 
improving clinical outcome as measured by both increased CD4+ T cell counts and body 
weight. Although the mechanisms driving this finding are unknown, it is possible that 
transient KMO inhibition had a durable impact on long-lived cells (or entrenched an 
important process) important for weight gain. KMO inhibition lowered T cell PD-1 
expression and increased naïve T cell frequency in SIV-infected animals; of note, KMO 
inhibition lowered PD-1 expression even within naïve and memory T cell subsets. 
Importantly, early PD-1 expression during acute SIV infection predicted clinical outcomes 
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of body weight and CD4+ T cell counts, suggesting a causal relationship between the 
KMOi-driven PD-1 decrease and clinical outcome.
The PD-1 pathway has been implicated in the exhaustion of virus-specific T cells during 
chonic HIV infection (7, 47, 48) and PD-1 blockade is being investigated as an intervention 
therapy in HIV/SIV infection. A humanized mouse model found improved CD4+ T cell 
counts with PD-1 blockade (42), consistent with our finding of a significant relationship 
between reduced PD-1 expression and improvement in CD4+ T cell counts. In some 
humanized mice and non-human primate studies, PD-1 blockade has resulted in enhanced 
HIV/SIV-specific responses and a decrease in plasma VL (42–44). Despite the reduced PD-1 
expression on both CD4+ and CD8+ T cells in KMOi-treated animals, we did not find 
evidence of increased antigen specific or polyclonal cytokine responses, even when 
normalized for the proportions of memory cells (Supplemental Fig. 4 and data not shown), 
nor was there a difference in VL between treatment groups. The link between the impact of 
PD-1 blockade on SIV-specific T cell responses and VL is uncertain, however, as some 
studies have shown limited therapeutic benefit of PD-1 blockade during chonic SIV 
infection, despite enhanced SIV-specific T cell responses (53, 54).
A number of key questions remain to be addressed. Although we have shown that KMO 
inhibition lowered PD-1 expression and increased naïve T cell frequencies, we do not know 
the mechanism(s) by which this occurred. Interestingly, a recent publication reported that 
KYN exposure directly upregulated PD-1 expression in CD8+ T cells via AhR activation 
(55), opposite to the repression of PD-1 we observed in the presence of KMOi mediated 
higher KYN concentrations. The reasons for this discrepancy are unknown, but Chen et al 
note that for maximal effect, TCR priming was required, whereas TCR signaling would have 
been largely absent in our study.
The increased frequencies of naïve T cells could result from improved thymic function, 
differential rates of thymocyte/naïve/memory T cell survival and proliferation, and/or 
alterations in the differentiation rate from naïve to CM. Although we found no evidence of 
KMO inhibition on thymic functionality in SCID-hu Thy/Liv mice inoculated with HIV-1, 
these studies were not definitive. Given recent evidence that exogenous KYN treatment 
leads to a dose-dependent inhibition of IL-2 signaling in memory CD4+ T cells, thereby 
inhibiting memory T cell survival and cytokine induced proliferation (56), future 
experiments might examine the proliferative capacity of naïve and memory T cell subsets ex 
vivo. No differences were observed in collagen deposition and TGFβ expression in LN, Treg 
frequencies, and plasma IL-7 levels, suggesting that enhanced preservation of LN 
fibroblastic reticular cell network in KMOi-treated animals is unlikely the cause of increased 
naïve T cell frequencies. Although Tregs may be expected to increase in the presence of 
KMOi due to the build up of KYN which induces AhR, (18), the resultant decrease in the 
downstream metabolite 3-HAA could cause a reduction in Treg (57). The engagement of 
two opposing mechanisms may explain the lack of significant changes in Treg frequencies.
It is notable that, in our proof of concept study, distinctions in clinical outcome between the 
treatment groups only became apparent months after cART initiation, even though KMOi 
was administered for just the first 4 weeks of the study. This demonstrates that changes 
Swainson et al. Page 11
J Immunol. Author manuscript; available in PMC 2020 August 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
which occur at the outset of infection can have profound effects at later timepoints. Most 
HIV-infected individuals initially present to the clinic many weeks to even years after 
infection and are soon thereafter put on cART, long after the window of very early KMOi 
treatment tested in our study. Based on our findings of KMO inhibition during acute SIV 
infection, we wonder whether KMO inhibition might also provide benefit in the setting of 
chonic cART-treated infection, where immune activation has been shown to persist.
The KP has also been implicated in the pathogenesis of HIV-associated neurocognitive 
disorder (HAND) (20, 27). It would thus also be of interest to evaluate KMO inhibition in 
the context of HIV dementia models, or other models of neuroinflammation that lead to an 
upregulation of the KP pathway, as CHDI-340246 can modulate the KP in the primate 
central nervous system (IMS, personal communication). Together, these data provide a 
rationale for testing the KMOi, CHDI-340246, as adjunctive treatment in SIV/HIV infection 
to slow progression of disease and to improve immune reconstitution.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Key Points
KMO inhibition improved clinical outcomes of CD4+ T cell counts and body weight
KMO inhibition increased naïve T cell frequency and lowered PD-1 expression
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Figure 1. Study Design.
Timeline of treatment and sampling. Juvenile macaques were infected i.v. with SIVmac251 
and treated for 4 weeks with KMOi CHDI-340246, or vehicle alone (8 animals per group). 
At 14 weeks post infection (p.i.), cART regimen was administered to all animals though the 
end of the study. Peripheral blood, peripheral LN, and RB were sampled at the indicated 
timepoints.
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Figure 2. KMO inhibition increases CD4+ T cell counts and body weight in SIV-infected animals.
Graphs indicate clinical outcomes in KMOi-treated (black) and control animals (grey) with 
mean+/−SE (upper) and individual animals (lower). Grey shading indicates the dosing 
period and the vertical line shows cART initiation. (A) Y axis represents the circulating 
CD4+ T cell count. (B) Y axis represents body weight as a percentage of baseline. (C) Y 
axis represents log10 plasma SIV RNA VL. Horizontal line indicates sensitivity limit of 
assay (50 copies/ml). Differences between treatment groups in the change from baseline 
were assessed with linear mixed models.
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Figure 3. The KMOi CHDI-340246 disrupts the KP and prevents SIV-induced increases in 
downstream metabolites.
Concentrations of KMOi CHDI-340246 and KP metabolites were quantified in plasma by 
LC/MS/MS analysis. (A) The KP and point of KMO inhibition by CHDI-340246. (B) 
CHDI-340246 plasma concentrations during the 24 h after first and last dose. Mean +/− 
SEM of all treated animals is represented. (C) KP metabolite plasma concentrations during 
the 24 h after first dose. Mean +/− SEM of treated (black) and control animals (grey) is 
represented. Levels of 3HAA were low and in some cases below the limit of quantitation, 
and therefore considered unreliable to quantify. (D) Plasma concentrations of KYN (upper 
panel) and QA (lower panel) during the first 56 days after SIV infection. Mean + SEM of 
treated animals (black) and control animals (grey) is represented. Differences between 
treatment groups at indicated timepoints was assessed using Wilcoxon rank sum analysis.
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Figure 4. KMO inhibition lowers PD-1 expression in CD4+ and CD8+ T cells in SIV-infected 
animals.
Grey shading indicates the dosing period and the vertical line shows cART initiation. Graphs 
indicate % of CD4+ T cells (A) and CD8+ T cells (B) positive for the indicated activation 
markers in pLN as measured by flow cytometry. KMOi-treated (black) and control animals 
(grey) are represented with mean+/−SE shown in upper panels and individual animals in 
lower panels. Differences between treatment groups in the change from baseline were 
assessed with linear mixed models.
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Figure 5. KMO inhibition increases naïve CD4+ and CD8+ T cell frequency in SIV-infected 
animals.
Grey shading indicates the dosing period and the vertical line shows cART initiation. Graphs 
indicate % of CD4+ T cells (A) and CD8+ T cells (B) identified as naïve, central memory 
(CM), or effector memory (EM) in pLN, as measured by flow cytometry. KMOi-treated 
(black) and control animals (grey) are represented with mean+/−SE shown in upper panels 
and individual animals in lower panels. Differences between treatment groups in the change 
from baseline were assessed with linear mixed models.
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Figure 6. KMO inhibition lowers PD-1 expression within naïve and memory CD4+ and CD8+ T 
cell subsets in SIV-infected animals.
Grey shading indicates the dosing period and the vertical line shows cART initiation. Graphs 
indicate % of CD4+ T cells (A) and CD8+ T cells (B) positive for PD-1 within naïve, central 
memory (CM), or effector memory (EM) subsets in pLN, as measured by flow cytometry. 
KMOi-treated (black) and control animals (grey) are represented with mean+/−SE shown in 
upper panels and individual animals in lower panels. Differences between treatment groups 
in the change from baseline were assessed with linear mixed models.
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Figure 7. Early PD-1 expression during acute SIV infection predicts clinical outcomes of body 
weight and CD4+ T cell counts.
To investigate the impact of PD-1 expression pre- and post-treatment on subsequent clinical 
outcomes, linear regression was used to test for associations between the frequencies of 
PD-1+ T cells in CD4+ T cells (upper panels) and CD8+ T cells (lower panels) at timepoints 
−2 weeks (pre-treatment baseline), 4 weeks (end of treatment) and 8 weeks p.i. vs. the 
clinical outcome variables of body weight (A) and CD4+ T cell counts (B) at 48 weeks p.i. 
Spearman r and p values are indicated in each panel. KMOi-treated animals are indicated in 
black and control animals in grey.
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